Carotid & Intracranial Stenosis Treatment
Carotid & Intracranial Stenosis Treatment
There is one treatment that applies at both sites, and it comes first: intensive medical therapy. An antiplatelet, a statin taken to a target rather than a dose, blood pressure controlled, diabetes treated, smoking stopped. Everything else on this page is added on top of that, never substituted for it — and the part most often underdone is that medical therapy itself. Beyond it, the two sites diverge. Symptomatic carotid narrowing was studied for decades, and opening or removing the plaque in selected patients with severe narrowing reduces the risk of a further stroke. Intracranial narrowing was studied later and the answer went the other way: in the trial that compared stenting with intensive medical therapy, the medical arm did better.
Medical therapy: the part that does the work
Intensive medical therapy is not a holding action while something else is decided. It is the treatment, and in a patient with an intracranial narrowing it is close to the whole of it. It has four or five components, and the difference between a patient on all of them and a patient on one is larger than most patients are told.
An antiplatelet agent is used to reduce the chance of a clot forming on the plaque. Which one, and whether two are used together and for how long, depends on whether the patient has had an event and on the bleeding risk. A statin at a target rather than a dose — the aim is a level, and the dose is adjusted to reach it, with the addition of another agent where the statin alone does not get there. Blood pressure control, because it acts on two risks at once. Treatment of diabetes where it is present. And smoking cessation, which is the single change with the largest effect and the one most often left to the patient to manage alone.
Why it is called intensive, and why it matters: in the trial of intracranial stenosis, the arm that did best was not the stenting arm but the medical arm, and the medical therapy in that trial was delivered deliberately and to targets, with a structured programme for blood pressure, lipids and lifestyle alongside the drugs. The comparison was not against a prescription; it was against a programme.
It also treats more than the lesion in front of you. A patient with a carotid narrowing has a vascular condition, and the coronary arteries are where a substantial share of their future events will occur. The statin and the blood pressure control work there as well.
Symptomatic carotid narrowing: where opening it earns its place
This is the situation in which the evidence for intervention is longest-standing and clearest: a patient who has had a transient attack, a visual loss or a stroke in the territory of the artery, and who has severe narrowing. In the trials that established it, operating on top of medical therapy reduced the risk of a further stroke in that territory compared with medical therapy alone.
Three conditions are attached to that, and they are the ones that get lost between a trial result and a clinic letter. The benefit depends on the complication rate of the operator and the centre — an operation that prevents a stroke in two years is undone if it causes one in two days. The benefit is greater the sooner it is done after the event, because the risk of recurrence is highest in the first days and weeks. And it is added to medical therapy, not given instead of it.
It is also a benefit in the territory of that artery, over the years that follow, and not a promise about the patient's whole vascular future. A patient who has a carotid procedure still needs the statin, the antiplatelet, the blood pressure control and the follow-up, and is still at risk from disease elsewhere. Saying this plainly is not pessimism; it is what stops a patient from treating the operation as the end of the matter.
Endarterectomy or stenting: two procedures, two profiles
They reach the same plaque by different routes and they are not old and new versions of one operation. Carotid endarterectomy opens the neck, clamps the artery, removes the plaque from inside and closes the vessel. Carotid artery stenting reaches it from inside, through a catheter usually introduced at the groin or the wrist, and opens the narrowing with a balloon and a stent.
What differs is which way the risks fall, and the answer is not the same at every age. Endarterectomy carries the risks of a neck operation — injury to the nerves around the artery, a haematoma at the wound, and the cardiac risk of any operation under anaesthesia. Stenting avoids the incision but carries a different profile: a higher rate of events around the procedure in older patients, and a higher rate of restenosis over the years that follow. Trials comparing them found the balance shifting with age, alongside differences in the rates of heart attack and of cranial nerve injury between the two.
Which is offered depends on anatomy as much as on age: where the plaque sits relative to the jaw and the skull base, whether there has been previous surgery or radiotherapy in the neck, whether the arch and the vessels leading up to it are favourable for a catheter, and how calcified the lesion is. It is decided by the team that would perform it, from the images, and it is reasonable to ask why one was recommended over the other.
Asymptomatic narrowing: a genuinely contested question
Whether to intervene on a narrowing that has never caused a symptom is one of the more honestly disputed questions in this field, and a patient is entitled to hear the argument rather than a recommendation made to sound settled. The trials that showed a benefit were conducted when medical therapy was far less intensive than it is now. Since then, the stroke rate on modern medical therapy for asymptomatic narrowing has fallen substantially, which shrinks the absolute benefit that any procedure could add.
What is not disputed is what should happen regardless of which way the decision goes. The medical therapy should be complete and to target. The follow-up should be arranged with a date rather than left open. And the patient should know the specific symptoms that would bring them back immediately. A patient told "nothing needs doing" and then not followed at all is being managed worse than either of the two options.
Where intervention is discussed, the features that tend to move the conversation are progression of the narrowing on serial imaging, a change in the plaque towards ulceration, evidence of silent injury downstream on brain imaging, and impaired perfusion. Each of those is a reason to look again, and none of them is a reason to act without the complication rate of the proposed procedure stated alongside the benefit.
Intracranial narrowing: where the trial went the other way
This is the section that most changes what a patient expects. Intracranial atherosclerotic stenosis — of the middle cerebral artery, the intracranial carotid, or the vertebral and basilar arteries — was studied in a trial that randomised patients with a recent event to stenting plus medical therapy or to intensive medical therapy alone. The trial was stopped early. The stenting arm had a higher rate of stroke and death in the period around the procedure, and the medical arm did better over follow-up.
The reason is worth stating, because it is not that stenting failed to open the vessel. It opened it. What happened is that events caused by the procedure itself — emboli released during it, bleeding into the brain afterwards, and injury to the small perforating branches that come off the vessel being treated — outweighed the strokes prevented. The intracranial vessels are small, they run in a confined space, and the branches they give off supply deep structures with little alternative supply. Squeezing plaque in one place can push it into a branch, and that is what the name given to that mechanism describes.
So stenting for intracranial stenosis is not abolished, but it is reserved. It is discussed where a patient has recurrent events despite properly delivered medical therapy, where the lesion is accessible and the anatomy favourable, and in a centre whose own procedural complication rate is low enough for the calculation to work. What it is not is the default answer to a percentage on a report.
Complete occlusion, and why bypass is not the answer
When the artery has closed completely rather than narrowed, the situation is different from severe stenosis. There is no channel to open, and the brain is being supplied by collaterals. The idea of connecting an artery from the scalp to a vessel on the brain — an extracranial-to-intracranial bypass — is an old one, and it was tested properly: a randomised trial in patients with symptomatic carotid occlusion found that bypass did not reduce recurrent stroke compared with medical therapy.
It is worth saying why, because the intuition behind the operation is reasonable and the result is still counter-intuitive. The surgery does add flow, and it demonstrably improves the appearance of perfusion studies. What it did not do was prevent the next stroke. The events in these patients are largely embolic rather than haemodynamic, and a bypass does not stop emboli.
Bypass therefore has a place in neurosurgery — it is the treatment in moyamoya disease, where the problem is progressive flow failure in a young circulation — but it is not a treatment for atherosclerotic carotid occlusion, and a patient offered it for that indication should ask what evidence is being relied on.
After the procedure, and what follows
What follows a carotid procedure is short. Most patients are discharged within a few days, with monitoring of blood pressure in the first period because both too high and too low are problems — high because of the operated vessel and the wound, low because the pressure-sensing mechanism at the bifurcation has been disturbed. A scan of the vessel is performed before discharge or soon after.
What follows the diagnosis is long, and it is the part that decides the outcome. The medical therapy continues indefinitely — the antiplatelet, the statin at its target, the blood pressure, the diabetes treatment, no smoking. Imaging of the vessel is repeated at intervals to see whether this narrowing is changing and whether the other side has developed disease. And the patient is told the symptoms that would bring them back the same day.
Where a stroke has already occurred, rehabilitation is part of the plan rather than something arranged afterwards. Recovery continues over months, and the deficits that remain at the end of that period are the ones that determine what support is needed. Improving the vessel does not undo the stroke that preceded it, which is the reason the whole of this page sits downstream of getting the medical therapy right in the first place.